Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ultragenyx Pharmaceutical (RARE) Stock Price
Media coverage about Ultragenyx Pharmaceutical (NASDAQ:RARE) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6439531677432 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- RARE Disease Concern Appears Undervalued – Seeking Alpha (seekingalpha.com)
- Ultragenyx Pharmaceutical Inc. (RARE) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Emil D. Kakkis Purchases 7,500 Shares of Ultragenyx Pharmaceutical Inc. (RARE) Stock (americanbankingnews.com)
- Ultragenyx Pharmaceutical Inc (RARE) Shares Trickle Lower For the Week – Evergreen Caller (evergreencaller.com)
- Ultragenyx Pharmaceutical Inc. (RARE) is at $51.40 per share and … – Stocks Gallery (stocksgallery.com)
Several research firms recently commented on RARE. Jefferies Group LLC reissued a “hold” rating and set a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, May 8th. Stifel Nicolaus restated a “buy” rating and issued a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reduced their price target on shares of Ultragenyx Pharmaceutical from $84.00 to $79.00 and set an “equal weight” rating for the company in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $74.82.
Shares of Ultragenyx Pharmaceutical (RARE) opened at 54.35 on Wednesday. The stock’s market cap is $2.31 billion. Ultragenyx Pharmaceutical has a 52-week low of $50.49 and a 52-week high of $91.35. The firm has a 50-day moving average of $63.00 and a 200-day moving average of $66.10.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same quarter last year, the company posted ($1.46) earnings per share. On average, equities analysts expect that Ultragenyx Pharmaceutical will post ($7.21) EPS for the current fiscal year.
In related news, CEO Emil D. Kakkis acquired 7,500 shares of the company’s stock in a transaction on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares in the company, valued at $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 9.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ultragenyx Pharmaceutical (RARE) Stock Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/30/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-ultragenyx-pharmaceutical-rare-stock-price.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.